Please provide your email address to receive an email when new articles are posted on . The humoral response to BP180 and BP230 antigens is weakened in certain patients with gliptin-associated bullous ...

Data from two trials designed to test the cardiovascular safety of the dipeptidyl peptidase 4 inhibitors saxagliptin and alogliptin, respectively, indicate that these drugs do not increase the ...

New diabetes drug lowers cost by 80% With the launch of teneligliptin molecule, the popular gliptin category has witnessed a price erosion of over 80% in the last six months, bringing down the cost ...

(HealthDay News) — Gliptin treatment is associated with increased acute pancreatitis risk, according to research published online Sept. 22 in Diabetes Care. Ivan Tkac, M.D., Ph.D., from Pasteur ...

India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version ...

MUMBAI: A new anti-diabetes drug from the ‘gliptin’ family soon to be launched in India promises to lower treatment cost for patients by 55-60%. The launch of ‘Teneligliptin’ by Mumbai-based Glenmark ...

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of ...

Ahmedabad-based Zydus Cadila is launching an anti-diabetic drug teneligliptin at an aggressive price of Rs 7 per day, almost 1/6th the price at which gliptins were initially launched in India.

A completely new drug in the ‘gliptin’ family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%. With the launch of the teneligliptin molecule, the popular ...